CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activationJing Gao, Lin Shen|Journal for ImmunoTherapy of Cancer|2023Cited by 39